YL201

YL201 is an antibody-drug conjugate developed by MediLink Therapeutics (Suzhou). Its target is B7-H3 (the sponsor names B7-H3). ClinicalTrials.gov describes the intervention as: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle. It is the investigational product in 9 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06629597 (A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)), NCT06612151 (A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）) and NCT07739758 (A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer), in nasopharyngeal carcinoma, non-small-cell lung cancer, small-cell lung cancer and prostate cancer. The largest, NCT06057922, plans to enrol 990 participants with primary completion expected 2026-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.